论文部分内容阅读
目的探讨双重血浆置换(DFPP)对重症肌无力(MG)的治疗效果。方法选择18例MG患者,其中男性8例,女性10例;年龄21~68岁,平均年龄38.2岁。进行DFPP治疗76次,平均4.2次,观察治疗前后许氏绝对与相对评分法(ARS-MG)和MG日常生活量表(MG-ADL)评分,同时对患者治疗前后空腹血标本乙酰胆碱受体抗体(AchRAb)水平进行监测。结果痊愈6例,显效9例,好转2例,无效1例,总有效率83.3%。DFPP治疗前后ARS-MG绝对评分[(18.72±5.13)分vs(9.56±4.08)分]、MG-ADL评分[(9.61±1.65)分vs(4.61±1.38)分]和AchRAb水平[(297.55±89.10)pmol/L vs(177.38±59.72)pmol/L]差异有显著统计学意义(P<0.01)。结论 DFPP能有效缓解患者的临床症状,降低患者体内AchRAb水平,是一种有效的治疗方法 。
Objective To investigate the therapeutic effect of double plasmapheresis (DFPP) on myasthenia gravis (MG). Methods 18 cases of MG patients, including 8 males and 10 females; aged 21 to 68 years, mean age 38.2 years. 76 patients were treated with DFPP for an average of 4.2 times. The ARS-MG and MG-ADL scores before and after treatment were observed. The levels of acetylcholine receptor antibody (AchRAb) level monitoring. Results cured in 6 cases, markedly effective in 9 cases, improved in 2 cases, ineffective in 1 case, the total effective rate was 83.3%. The absolute score of ARS-MG (18.72 ± 5.13 vs 9.56 ± 4.08), MG-ADL score (9.61 ± 1.65 vs 4.61 ± 1.38) and AchRAb level (297.55 ± 89.10) pmol / L vs (177.38 ± 59.72) pmol / L]. There was significant difference between the two groups (P <0.01). Conclusion DFPP can effectively alleviate the clinical symptoms of patients and reduce the level of AchRAb in patients, which is an effective treatment.